UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
Zafiris J. “Jeff” Daskalakis, MD, PhD, has been named chair of the Department of Psychiatry at University of California San Diego School of Medicine.
Researchers at UC San Diego School of Medicine are among the contributors to a package of 10 studies in the journal Nature, describing the latest results from the ongoing Encyclopedia of DNA Elements project, a worldwide effort led by the NIH to understand how the human genome functions.
UC San Diego Health is ranked first in San Diego and sixth in California, placing it among the nation’s best hospitals, according to the 2020-2021 U.S. News & World Report. Eight common procedures and conditions were also rated “high performing.”
Researchers at Ludwig Institute for Cancer Research and University of California San Diego School of Medicine report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth.
The San Diego Union-Tribune, June 23
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
